Our products

Connecting Canadian patients with proven treatments from around the world.

Celystra identifies and acquires innovative therapies developed by international partners and brings them to Canadian patients who need them most. For each product we commercialize, we assume full responsibility for its regulatory submission, Health Canada approval process, and ongoing safety oversight — ensuring that every treatment meets the most stringent standards before reaching the patients it is intended to serve.

Health Canada-approved

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam diam massa, egestas eget mauris non, fringilla efficitur nulla.

TRYNGOLZA is a GalNAc-conjugated antisense oligonucleotide inhibitor of apolipoprotein C-III (apoC-III)

DAWNZERA is an antisense oligonucleotide (ASO) that binds to prekallikrein (PKK) mRNA to limit plasma protein production

Pending approval

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam diam massa, egestas eget mauris non, fringilla efficitur nulla.

TRYNGOLZA is a GalNAc-conjugated antisense oligonucleotide inhibitor of apolipoprotein C-III (apoC-III)

DAWNZERA is an antisense oligonucleotide (ASO) that binds to prekallikrein (PKK) mRNA to limit plasma protein production

TRYNGOLZA is a GalNAc-conjugated antisense oligonucleotide inhibitor of apolipoprotein C-III (apoC-III)

DAWNZERA is an antisense oligonucleotide (ASO) that binds to prekallikrein (PKK) mRNA to limit plasma protein production